drugset / Trial / NCT07532252
Daridorexant for Alcohol Use Disorder
Phase 2
Not yet recruiting
150 enrolled
Johns Hopkins University
Idorsia Pharmaceuticals Ltd. · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will test whether the dual orexin receptor antagonist (DORA) daridorexant reduces alcohol craving and use and improves total sleep time among patients with co-occurring alcohol use disorder and sleep disturbance. The study will assess the role of the orexin system in modulating alcohol craving and use in a real-world treatment setting.
Timeline
- Start
- 2027-01-01
- Primary completion
- 2030-08-01
- Completion
- 2031-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daridorexant | Small molecule | 50 mg | Oral |